Natixis Advisors LLC Buys 335,667 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Natixis Advisors LLC increased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 198.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 504,534 shares of the company’s stock after purchasing an additional 335,667 shares during the quarter. Natixis Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $11,120,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Picton Mahoney Asset Management boosted its holdings in shares of Teva Pharmaceutical Industries by 50.7% in the 4th quarter. Picton Mahoney Asset Management now owns 633,149 shares of the company’s stock valued at $13,953,000 after purchasing an additional 213,041 shares in the last quarter. Skandinaviska Enskilda Banken AB publ boosted its stake in Teva Pharmaceutical Industries by 13.7% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 1,432,374 shares of the company’s stock valued at $31,971,000 after buying an additional 172,122 shares in the last quarter. Achmea Investment Management B.V. grew its position in Teva Pharmaceutical Industries by 49.8% in the fourth quarter. Achmea Investment Management B.V. now owns 860,894 shares of the company’s stock valued at $18,975,000 after acquiring an additional 286,371 shares during the last quarter. Vestcor Inc lifted its holdings in shares of Teva Pharmaceutical Industries by 13.4% in the fourth quarter. Vestcor Inc now owns 16,896 shares of the company’s stock worth $372,000 after acquiring an additional 1,990 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 45.3% in the fourth quarter. Farther Finance Advisors LLC now owns 6,592 shares of the company’s stock worth $145,000 after acquiring an additional 2,054 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Bank of America cut their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Piper Sandler upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. Barclays decreased their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Stock Down 1.2 %

Shares of NYSE TEVA opened at $16.29 on Thursday. Teva Pharmaceutical Industries Limited has a 1 year low of $12.51 and a 1 year high of $22.80. The stock has a market capitalization of $18.46 billion, a P/E ratio of -11.23, a P/E/G ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company has a 50-day moving average price of $17.99 and a 200-day moving average price of $18.25.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares of the company’s stock, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.